# Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer

> **NCT04305236** · PHASE2 · TERMINATED · sponsor: **University of California, Irvine** · enrollment: 1 (actual)

## Conditions studied

- Breast Neoplasm
- Hormone Receptor Positive Breast Carcinoma

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT04305236
- **Lead sponsor:** University of California, Irvine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-23
- **Primary completion:** 2022-02-16
- **Final completion:** 2022-02-16
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Halted due to study funding
- **Last updated:** 2023-06-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04305236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04305236, "Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04305236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*